Historical aspects and milestones in HCL 7
59. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti- 65. Filleul B, Delannoy A, Ferrant A, et al. A single course of
CD20 monoclonal antibodies (Mabthera) in patients with 2-chloro-deoxyadenosine does not eradicate leukemic cells in
progressed hairy cell leukemia. Haematologica 2001;86: hairy cell leukemia patients in complete remission. Leukemia
1046–1050. 1994;8:1153–1156.
60. Forconi F, Toraldo F, Sozzi E, et al. Complete molecular 66. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in
remission induced by concomitant cladribine – rituximab refractory hairy cell leukemia to a recombinant immunotoxin.
treatment in a case of multi-resistant hairy cell leukemia. Leuk Blood 1999;94:3340–3348.
Lymphoma 2007;48:2441–2443. 67. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the
61. Else M, Osuji N, Forconi F, et al. The role of rituximab in anti-CD22 recombinant immunotoxin BL22 in chemother-
combination with pentostatin or cladribine for the treatment of apy-resistant hairy-cell leukemia. N Engl J Med 2001;345:
recurrent/refractory hairy cell leukemia. Cancer 2007;110: 241–247.
2240–2247. 68. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II
62. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22)
minimal residual disease in hairy cell leukemia. Blood 2006; in patients with hairy cell leukemia. J Clin Oncol 2009;27:
107:4658–4662. 2983–2990.
63. Wheaton S, Tallman MS, Hakimian D, et al. Minimal 69. Bang S, Nagata S, Onda M, et al. HA22 (R490A) is a
residual disease may predict bone marrow relapse in patients recombinant immunotoxin with increased antitumor activity
with hairy cell leukemia treated with 2-chlorodeoxyadenosine. without an increase in animal toxicity. Clin Cancer Res
Blood 1996;87:1556–1560. 2005;11:1545–1550.
64. Konwalinka G, Schirmer M, Hilbe W, et al. Minimal re- 70. Grever M, Kopecky K, Foucar MK, et al. Randomized
sidual disease in hairy-cell leukemia after treatment with comparison of pentostatin versus interferon a- 2a in previously
2-chlorodeoxyadenosine. Blood Cells Mol Dis 1995;21: untreated patients with hairy cell leukemia: an intergroup
142–151. study. J Clin Oncol 1995;13:974–982.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46